Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

43P - Ocular adverse events due to PD-1 and PD-L1 checkpoint inhibitors: A retrospective review of FDA adverse events reporting system (FAERS)

Date

09 Dec 2020

Session

e-Poster Display Session

Topics

Immunotherapy;  Supportive Care and Symptom Management

Tumour Site

Presenters

Yamini Sahu

Citation

Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391

Authors

Y. Sahu1, J. Ensor2, E. Burns3, G. Sahu4, S. Iyer5

Author affiliations

  • 1 Safdarjung hospital, New Delhi/IN
  • 2 Houston methodist research institute, Houston/US
  • 3 Houston Methodist Hospital, Houston/US
  • 4 Creighton University School of Medicine, North Platte/US
  • 5 UT MD Anderson Cancer Center, Houston/US
More

Abstract 43P

Background

Immune checkpoint inhibitors (ICIs) targeting program cell death protein 1 (PD-1) and program cell death ligand 1 (PD-L1) have improved outcomes for many cancer subtypes but are associated with toxicity due to immune related adverse events (irAEs) which can affect any organ. In this study we queried FAERS (a pharmacovigilance database) to find out rate of ocular toxicity due to ICIs targeting PD-1 and PD-L1.

Methods

We retrospectively queried FAERS from January 1,2015 to June 30, 2020 for “dry eyes”, “uveitis”, “eye inflammation”, “retinal detachment”, “ocular myasthenia”, “ulcerative keratitis” and “optic neuropathy” due to five FDA approved PD-1/PD-L1 inhibitors atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab. Disproportionality signal analysis was done by calculating reporting odds ratio (ROR) with 95% confidence interval (CI). ROR was considered significant when lower limit of 95% CI was >1. Chi-square or fishers exact test was used to calculate p value as appropriate.

Results

Total adverse events (AEs) from all drug were 10,687,588 out of which 78,081 were due to PD-1/PD-L1 ICIs.Total AEs for dry eyes,uveitis,eye inflammation, retinal detachment, ocular myasthenia, ulcerative keratitis and optic neuropathy were 75,204,21,49,16,13 and 11. ROR for dry eyes, uveitis, eye inflammation, retinal detachment, ocular myasthenia, ulcerative keratitis and optic neuropathy was 0.7(95% CI 0.5,0.9) (p=0.005),7.6(95% CI 6.6-8.8) (p<0.0001),0.9(95% CI 0.6-1.5)(p=0.9),2.3(95% 1.7-3.1) (p<0.0001),23.1(95% CI 13.6,39.3) (p<0.001), 1.9(95% CI 1.1,3.3) (p=0.01) and 2.3(95% CI 1.3-4.3) (p=0.0085) respectively.

Conclusions

Ocular irAEs are rare due to PD-1/PD-L1 ICIs. ROR for ocular myasthenia, optic neuropathy, retinal detachment, ulcerative keratitis and uveitis was elevated due to PD-1/PD-L1 ICIs.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S.P. Iyer: Research grant/Funding (self): Merck; Research grant/Funding (self): Seattle Genetics; Research grant/Funding (self): rhizen; Research grant/Funding (self): Spectrum; Research grant/Funding (self): Trillium; Research grant/Funding (self): CrisprRx. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.